Fig. 2

Systemic expansion of neutrophils in mice bearing SDCSC-derived tumors. a The percentage of circulating monocytes, neutrophils, eosinophils, basophils, and lymphocytes from indicated healthy mice (N = 8), mice bearing CT26 parental cell-derived tumor (N = 3), and mice bearing CT26-SDCSC-derived tumor (N = 5). Data represent the mean ± SEM. *P < .05, ***P < .001. b Gating strategy for detecting neutrophils and monocytes. c Percentage of neutrophils (PMN-MCs, polymorphonuclear myeloid cells) and monocytes (M-MCs, mononuclear myeloid cells) in bone marrows (left panels), spleens (middle panels), and primary tumors (right panels) harvested from healthy mice (N = 5), mice bearing parental cell-derived tumor (N = 4 for bone marrow and spleen groups, N = 3 for tumor group), and mice bearing SDCSC-derived tumor (N = 5 for bone marrow and spleen groups, N = 4 for tumor group). The data represent mean ± SEM. *P < .05, **P < .01, ***P < .001. d Percentage of CD11b⁺/Gr-1⁺ neutrophils (upper panel) and CD11b⁺/Ly6G^HIgh/Ly6C^low-neg neutrophils in ex-vivo cultured bone marrow cells. Indicated medium was mixed with complete RPMI medium at 1:1 ratio for 72 h. Mock, complete DMEM medium; SCM, stem cell medium; Sph-CM, condition medium from SDCSCs; Sph-CM ex-del, exosome-removed condition medium of SDCSCs. *P < .05, **P < .01, ***P < .001